Jul 14, 2014

CardioCell Begins Phase 2A Trial Of itMSC In HF

Stemedica Cell Technologies subsidiary CardioCell announced that it has initiated its Phase IIA clinical trial investigating its proprietary ischemia-tolerant mesenchymal stem cells (itMSCs) in patients with chronic heart failure (HF) with non-ischemic cardiomyopathy. READ FULL ARTICLE